489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
278 citations
,
May 2013 in “Ca” Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
48 citations
,
March 2021 in “Frontiers in Cell and Developmental Biology” Human mesenchymal stem cells show promise for treating skin diseases, but more research is needed to improve treatments.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
28 citations
,
August 2020 in “F1000Research” Better understanding and new treatments for hidradenitis suppurativa are emerging, but more research is needed.
24 citations
,
June 2013 in “Journal of neuroendocrinology” Neuroactive steroids and the enzyme 5α-reductase might be involved in the development of Tourette's syndrome.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
21 citations
,
April 2025 in “MedComm” Alopecia areata causes unpredictable hair loss, and more research is needed to fully understand and treat it effectively.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
7 citations
,
May 2022 in “International Journal of Environmental Research and Public Health” Isotretinoin therapy for acne can cause many reversible side effects, mainly mild skin conditions, and patient understanding of these effects can improve treatment adherence.
5 citations
,
December 2024 in “Anais Brasileiros de Dermatologia” Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
2 citations
,
December 2021 in “F1000Research” Most people in South India lack knowledge about managing COVID-19 at home.
2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
1 citations
,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
1 citations
,
March 2023 in “Phytochemistry Reviews” CBD may improve skin and hair health, but its effective use and safety need more research.
1 citations
,
March 2022 in “F1000Research” Training programs are needed to improve home COVID-19 management practices.
1 citations
,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
1 citations
,
January 2022 in “Annals of Dermatology” Dutasteride is more effective than finasteride for long-term hair growth in men with androgenic alopecia.
1 citations
,
May 2020 in “Reproductive Endocrinology” The document concludes that hair loss and acne in women can be due to both androgen-related and unrelated causes, requiring a collaborative treatment approach.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.